Janux Therapeutics (JANX) Prepaid Assets (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Prepaid Assets of $893000.0 for Q1 2026, down 90.29% year-over-year from $9.2 million in Q1 2025, and down 51.83% quarter-over-quarter from $1.9 million in Q4 2025.
Analysis
Janux Therapeutics (JANX) Prepaid Assets (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Prepaid Assets for 7 consecutive years, with $893000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 90.29% year-over-year to $893000.0; the TTM figure through Mar 2026 stood at $893000.0 (down 90.29% YoY), while the FY2025 annual figure was $1.9 million, down 21.24% from the prior year.
- Prepaid Assets slipped to $893000.0 in Q1 2026 per JANX's latest filing, from $1.9 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $9.5 million in Q2 2025 and bottomed at $893000.0 in Q1 2026.
- Historically, Prepaid Assets has averaged $5.1 million across 5 years, with a median of $5.1 million in 2022.
- Annual changes were most pronounced in 2025 — Prepaid Assets jumped 398.54% — and 2026, when it slumped 90.29%.
- Janux Therapeutics' Prepaid Assets stood at $5.4 million in 2022, then sank by 57.26% to $2.3 million in 2023, then grew by 1.55% to $2.4 million in 2024, then declined by 21.24% to $1.9 million in 2025, then sank by 51.83% to $893000.0 in 2026.
- Business Quant data shows JANX's Prepaid Assets at $893000.0 in Q1 2026, $1.9 million in Q4 2025, and $9.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.28 Mn |
| Mar 31, 2026 | 10.66 Mn |
| Dec 31, 2025 | 9.32 Mn |
| Sep 30, 2025 | 9.09 Mn |
| Jun 30, 2025 | 9.54 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2024 | 8.49 Mn |
| Sep 30, 2024 | 8.29 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 6.38 Mn |
| Dec 31, 2023 | 5.21 Mn |
| Sep 30, 2023 | 5.48 Mn |
| Jun 30, 2023 | 6.01 Mn |
| Mar 31, 2023 | 3.77 Mn |
| Dec 31, 2022 | 5.42 Mn |
| Sep 30, 2022 | 5.07 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Mar 31, 2022 | 3.45 Mn |
| Dec 31, 2021 | 2.05 Mn |
| Sep 30, 2021 | 2.08 Mn |